News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
Is Hyperliquid (HYPE) Poised for a Bullish Rally? This Emerging Fractal Setup Saying Yes!
CoinsProbe·2025/10/29 21:42
Pepe (PEPE) To Bounceback? This Emerging Fractal Setup Saying Yes!
CoinsProbe·2025/10/29 21:42
South Korea’s BDACS to Launch KRW1 Stablecoin on Circle’s Arc Blockchain
DeFi Planet·2025/10/29 21:39
Traditional Banks Embrace Stablecoins as BitGo Unveils Plug-and-Play Deposit Framework
DeFi Planet·2025/10/29 21:39
Deutsche Digital Assets and Safello launch staked Bittensor ETP
Coinjournal·2025/10/29 21:30
PancakeSwap taps Ondo to integrate real-world assets (RWAs) on BNB Chain
Coinjournal·2025/10/29 21:30
Ethereum Foundation launches institutional portal to boost enterprise adoption
Coinjournal·2025/10/29 21:30
Injective (INJ) completes its first community buyback worth $32 million
Coinjournal·2025/10/29 21:30
Bitcoin, altcoins slip as the Fed lowers interest rates by 25 basis points
Coinjournal·2025/10/29 21:30
Germany’s AfD party proposes Bitcoin as strategic asset
Coinjournal·2025/10/29 21:30
Flash
12:51
Vivos (OTC market code: RDGL) has received Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) and will initiate a human clinical feasibility study of its Radiogel® Precision Radionuclide Therapy™.This approval marks a key step forward for the clinical application of this innovative therapy, allowing the company to begin initial safety and feasibility assessments in humans. The Radiogel® technology is designed to enable precise radiation treatment within tumors and is expected to provide a new treatment option for cancer patients. The approved clinical study will collect essential data to lay the foundation for larger-scale clinical trials in the future.
12:51
Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level.This positive safety data lays the foundation for further exploration of higher doses and demonstrates the potential of this therapy in terms of patient tolerability.
12:51
Splash Beverage Group Inc. announces the issuance of $5.5 million in preferred stockMeanwhile, the company’s $5 million debt to Argent BioPharma Limited has been fully waived as a license consideration.
News